Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide.
OBJECTIVE
To present a case of spinal anesthesia in a patient suffering from carcinoid syndrome undergoing an inguinal hernia repair. In the past, regional anesthesia was considered unacceptable in these patients because of the possibility of intraoperative hypotension, hypertension, or bronchospasm. Recently, however, the preoperative use of octreotide, the synthetic analogue of the naturally occurring hormone somastatin, has been found to prevent these complications. Nevertheless, it remains unclear whether the use of this drug in patients with carcinoid syndrome allows the possibility of regional anesthesia.


RESULTS
We report the uneventful use of spinal anesthesia in a patient suffering from carcinoid syndrome treated with long-acting octreotide. With careful attention to volume status of the patient and low volume of local anesthetics (10 mg hyperbaric bupivacaine 0.5%) supplemented with intrathecal narcotics (fentanyl 20 micro g), we were able to prevent any episodes of intraoperative hypotension in this patient. Octreotide was available in the operating theatre in case of an emergency. One of the original aspects of this case report is that the patient received long-acting octreotide (once a month administration) instead of the usual daily dose. In addition this is one of the few reports of spinal anesthesia administered to a patient with carcinoid syndrome.


CONCLUSIONS
Preoperative octreotide may result in more favourable conditions for regional anesthesia in patients with carcinoid syndrome. However, further studies will be required to confirm the favourable outcome observed in this patient.
Department of Anesthesiology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel.
Sharon
S
Orbach-Zinger
Raphael
R
Lombroso
Leonid A
LA
Eidelman
D000368:Aged; D000775:Anesthesia, Spinal; D006552:Hernia, Inguinal / Q000150:complications / Q000601:surgery*; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007431:Intraoperative Complications / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000150:complications / Q000188:drug therapy*; D015282:Octreotide / Q000627:therapeutic use*; D011292:Premedication; D016896:Treatment Outcome
D006728:Hormones; D015282:Octreotide